Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€231.40

€231.40

0.130%
0.3
0.130%
€245.80
 
28.03.24 / Tradegate WKN: 866197 / Symbol: DHR / Name: Danaher / Stock / Machinery, Equipment & Components / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
The full analysis of the stock Danaher Corp. is only available for our menbers.
Not a member yet? Sign up for free!

Financial data and news for Danaher

sharewise wants to provide you with the best news and tools for Danaher, so we directly link to the best financial data sources.

News

Why Shares of Danaher Are Down Monday: https://g.foolcdn.com/editorial/images/749538/healthcare-lab-treatment-research-scientist-1.jpg
Why Shares of Danaher Are Down Monday

Shares of Danaher (NYSE: DHR) were down more than 14% as of Monday at 11:45 a.m. The industrial science and technology conglomerate announced Saturday it had completed the spinoff of its

Will Danaher stock hit new highs in 2024?: https://www.marketbeat.com/logos/articles/med_20240109140643_will-danaher-stock-hit-new-highs-in-2024.jpg
Will Danaher stock hit new highs in 2024?

Danaher Corporation (NYSE: DHR) shares went into a tailspin when the Abcam deal came into question, but the dip turned out to be a buying opportunity in this life-sciences company. The dip hit